A specialty eye-drug maker that sells tiny implants and injections to treat chronic retinal diseases, like a slow-release medicine pump for the back of the eye.
Annual revenue is tiny at USD 0.03-0.05B, with gross margins around 90% on existing products, but the company loses money every year (net losses of USD 0.07B-0.23B annually). All cash flow is from product sales; no recurring licensing income is visible.
Patents on its sustained-release implants and the YUTIQ/ILUVIEN delivery systems would deter generic competition, but regulators and big pharma like Regeneron and Roche are advancing rival long-acting eye treatments that could erode its niche.
Key events, in time order
Management discusses with Mizuho, attributes failure to anomalous cohort; future studies in focus
Q2 loss of $1.09/share vs $0.92 estimate; LUGANO data expected Aug 2026, LUCIA data expected Q4 2026
COMO and CAPRI trials enrolled over 480 participants in five months, demonstrating enthusiasm among retinal specialists and patients
None yet
None yet
The discussion centers on potential increasing enthusiasm for EyePoint's AXPAXLI within the retinal community, following scientific advisor calls and data releases. The focus is on fundamental thesis and community sentiment.
Main discussion
Different voices
Increasing unusual put option volume: $MDLN $ROST $VIK $IOVA $AAP $EYPT $ARE $OWL $LOGI $POWL $FN
$EYPT $OCUL listened twice now to Pravin & Jay call this week “Scientfic advisors “mentioned many times & also shared - have to wonder after hearing Pravin & one other Retinal specialist speak if enthusiasm for AXPAXLI is not increasing even more in Retinal community - would thin
$OCUL Pravin piper webcast 46 min worth listening to after $EYPT data 12 min mark on gets interesting https://investors.ocutx.com/events/event-details/piper-sandler-virtual-fireside-chat
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
